Sandu Pharmaceuticals Ltd (SANDUPHQ) is currently trading at 33.99 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Sandu Pharmaceuticals Ltd (SPL) is primarily engaged in the manufacturing and trading of Ayurvedic medicines, operating under its brand name SANDU. Established in 1985, SPL expanded its capabilities with a major project in Goa, initiated in 1994 and commenced production in 1996-97, marking a significant milestone in the company's growth journey. SPL's production facilities utilize modern material handling systems and maintain high standards of hygiene, ensuring the quality of its ayurvedic products, which are well-regarded for their minimal side effects. Ayurvedic products have a strong demand in India and internationally, presenting SPL with significant growth opportunities in domestic and export markets.

Over the past 52 weeks, Sandu Pharmaceuticals Ltd has traded between a low of ₹30.00 and a high of ₹50.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Sandu Pharmaceuticals Ltd has a market capitalization of approximately 32.84. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Sandu Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 21.05 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 32.84 Cr, Sandu Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Sandu Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Sandu Pharmaceuticals Ltd is 21.05. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The board meeting is scheduled for July 11, 2026, at 04:00 p.m.

The board meeting is scheduled for July 11, 2026 at 04:00 p.m.

The company stated the meeting is to place on record the demise of Managing Director Umesh B. Sandu and to record the board’s appreciation for his contribution.

The board meeting is scheduled for July 11, 2026, at 4:00 p.m.